Table 5.
The distribution of the CCL2 and CCR2 genotypes in AD patients, MCI patients, and control subjects.
| Control (n = 120) | MCI (n = 66) | AD (n = 310) | AD and MCI (n = 376) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GG | AG | AA | GG | AG | AA | GG | AG | AA | GG | AG | AA | |
| CCL2 | 39 | 53 | 28 | 22 | 36 | 8 | 84 | 163 | 63 | 106 | 199 | 71 |
| rs1024611 | (32.5%) | (44.2%) | (23.3%) | (33.3%) | (54.5%) | (12.1%) | (27.1%) | (52.6%) | (20.3%) | (28.2%) | (52.9%) | (18.9%) |
| Additive model | Ref | p = 0.26, adjusted p = 0.30* | p = 0.73, adjusted p = 0.71* | p = 1.00, adjusted p = 0.74* | ||||||||
| CCR2 | 75 | 40 | 5 | 42 | 22 | 2 | 185 | 108 | 17 | 227 | 130 | 19 |
| rs1799864 | (62.5%) | (33.3%) | (4.2%) | (63.6%) | (33.3%) | (3.0%) | (59.7%) | (34.8%) | (5.5%) | (60.4%) | (34.6%) | (5.1%) |
| Additive model | Ref | p = 0.75, adjusted p = 0.77* | p = 0.51, adjusted p = 0.69* | p = 0.62, adjusted p = 0.84* | ||||||||
MCI, mild cognitive impairment; AD, Alzheimer’s disease; CCL2, Chemokine ligand 2; CCR2, CC-chemokine receptor 2.
*Multivariate logistic regression model adjusting age, gender, and APOE ε4 carrier status.